おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Cogent Biosciences
company
About
Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.
- 101 - 250
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $65M
- Industries
- Biotechnology,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2014
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$65M
Cogent Biosciences has raised a total of
$65M
in funding over 2 rounds. Their latest funding was raised on
Jun 11, 2015 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 11, 2015 | Series B | $65M | 1 | — | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
